{"pmid":32435059,"title":"A suspicious role of interferon in the pathogenesis of SARS-CoV-2 by enhancing expression of ACE2.","text":["A suspicious role of interferon in the pathogenesis of SARS-CoV-2 by enhancing expression of ACE2.","Signal Transduct Target Ther","Su, Shan","Jiang, Shibo","32435059"],"journal":"Signal Transduct Target Ther","authors":["Su, Shan","Jiang, Shibo"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32435059","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1038/s41392-020-0185-z","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667521393838784512,"score":9.490897,"similar":[{"pmid":32298458,"title":"Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?","text":["Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?","Swiss Med Wkly","Negro, Francesco","32298458"],"journal":"Swiss Med Wkly","authors":["Negro, Francesco"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298458","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.4414/smw.2020.20249","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138493258039298,"score":58.437504},{"pmid":32303424,"pmcid":"PMC7152872","title":"Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19.","text":["Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19.","It has been reported that SARS-CoV-2 may use ACE2 as a receptor to gain entry into human cells, in a way similar to that of SARS-CoV. Analyzing the distribution and expression level of ACE2 may therefore help reveal underlying mechanisms of viral susceptibility and post-infection modulation. In this study, we utilized previously uploaded information on ACE2 expression in various conditions including SARS-CoA to evaluate the role of ACE2 in SARS-CoV and extrapolate that to COVID-19. We found that the expression of ACE2 in healthy populations and patients with underlying diseases was not significantly different. However, based on the elevated expression of ACE2 in cigarette smokers, we speculate that long-term smoking may be a risk factor for COVID-19. Analysis of ACE2 in SARS-CoV infected cells suggests that ACE2 is not only a receptor but is also involved in post-infection regulation, including immune response, cytokine secretion, and viral genome replication. Moreover, we constructed Protein-protein interaction (PPI) networks and identified hub genes in viral activity and cytokine secretion. Our findings may help clinicians and researchers gain more insight into the pathogenesis of SARS-CoV-2 and design therapeutic strategies for COVID-19.","J Autoimmun","Li, Guoping","He, Xiang","Zhang, Lei","Ran, Qin","Wang, Junyi","Xiong, Anying","Wu, Dehong","Chen, Feng","Sun, Jinlyu","Chang, Christopher","32303424"],"abstract":["It has been reported that SARS-CoV-2 may use ACE2 as a receptor to gain entry into human cells, in a way similar to that of SARS-CoV. Analyzing the distribution and expression level of ACE2 may therefore help reveal underlying mechanisms of viral susceptibility and post-infection modulation. In this study, we utilized previously uploaded information on ACE2 expression in various conditions including SARS-CoA to evaluate the role of ACE2 in SARS-CoV and extrapolate that to COVID-19. We found that the expression of ACE2 in healthy populations and patients with underlying diseases was not significantly different. However, based on the elevated expression of ACE2 in cigarette smokers, we speculate that long-term smoking may be a risk factor for COVID-19. Analysis of ACE2 in SARS-CoV infected cells suggests that ACE2 is not only a receptor but is also involved in post-infection regulation, including immune response, cytokine secretion, and viral genome replication. Moreover, we constructed Protein-protein interaction (PPI) networks and identified hub genes in viral activity and cytokine secretion. Our findings may help clinicians and researchers gain more insight into the pathogenesis of SARS-CoV-2 and design therapeutic strategies for COVID-19."],"journal":"J Autoimmun","authors":["Li, Guoping","He, Xiang","Zhang, Lei","Ran, Qin","Wang, Junyi","Xiong, Anying","Wu, Dehong","Chen, Feng","Sun, Jinlyu","Chang, Christopher"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303424","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jaut.2020.102463","keywords":["2019-ncov","ace2","covid-19","immune response","protein-protein interactions","sars-cov-2","susceptibility"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491065466883,"score":58.166782},{"pmid":32301957,"pmcid":"PMC7184357","title":"Weak Induction of Interferon Expression by SARS-CoV-2 Supports Clinical Trials of Interferon Lambda to Treat Early COVID-19.","text":["Weak Induction of Interferon Expression by SARS-CoV-2 Supports Clinical Trials of Interferon Lambda to Treat Early COVID-19.","Clin Infect Dis","O'Brien, Thomas R","Thomas, David L","Jackson, Sarah S","Prokunina-Olsson, Ludmila","Donnelly, Raymond P","Hartmann, Rune","32301957"],"journal":"Clin Infect Dis","authors":["O'Brien, Thomas R","Thomas, David L","Jackson, Sarah S","Prokunina-Olsson, Ludmila","Donnelly, Raymond P","Hartmann, Rune"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32301957","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1093/cid/ciaa453","keywords":["mers-cov","middle east respiratory syndrome","sars-cov","innate immunity","public health","severe acute respiratory syndrome","virology"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494783717376,"score":54.24442},{"pmid":32418715,"title":"COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons.","text":["COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons.","The outbreak of the novel SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) responsible for coronavirus disease 2019 (COVID-19) has developed into an unprecedented global pandemic. Clinical investigations in patients with COVID-19 has shown a strong upregulation of cytokine and interferon production in SARS-CoV2- induced pneumonia, with an associated cytokine storm syndrome. Thus, the identification of existing approved therapies with proven safety profiles to treat hyperinflammation is a critical unmet need in order to reduce COVI-19 associated mortality. To date, no specific therapeutic drugs or vaccines are available to treat COVID-19 patients. This review evaluates several options that have been proposed to control SARS-CoV2 hyperinflammation and cytokine storm, eincluding antiviral drugs, vaccines, small-molecules, monoclonal antibodies, oligonucleotides, peptides, and interferons (IFNs).","Cytokine Growth Factor Rev","Nile, Shivraj Hariram","Nile, Arti","Qiu, Jiayin","Li, Lin","Jia, Xu","Kai, Guoyin","32418715"],"abstract":["The outbreak of the novel SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) responsible for coronavirus disease 2019 (COVID-19) has developed into an unprecedented global pandemic. Clinical investigations in patients with COVID-19 has shown a strong upregulation of cytokine and interferon production in SARS-CoV2- induced pneumonia, with an associated cytokine storm syndrome. Thus, the identification of existing approved therapies with proven safety profiles to treat hyperinflammation is a critical unmet need in order to reduce COVI-19 associated mortality. To date, no specific therapeutic drugs or vaccines are available to treat COVID-19 patients. This review evaluates several options that have been proposed to control SARS-CoV2 hyperinflammation and cytokine storm, eincluding antiviral drugs, vaccines, small-molecules, monoclonal antibodies, oligonucleotides, peptides, and interferons (IFNs)."],"journal":"Cytokine Growth Factor Rev","authors":["Nile, Shivraj Hariram","Nile, Arti","Qiu, Jiayin","Li, Lin","Jia, Xu","Kai, Guoyin"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32418715","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.cytogfr.2020.05.002","keywords":["covid-19","coronavirus","interferons","recombinant","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667254896669229056,"score":53.781845},{"pmid":32411576,"pmcid":"PMC7220165","title":"SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors.","text":["SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors.","Lancet Respir Med","Milne, Stephen","Yang, Chen Xi","Timens, Wim","Bosse, Yohan","Sin, Don D","32411576"],"journal":"Lancet Respir Med","authors":["Milne, Stephen","Yang, Chen Xi","Timens, Wim","Bosse, Yohan","Sin, Don D"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32411576","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/S2213-2600(20)30224-1","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666897319187972096,"score":47.767426}]}